Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis | Zendy

Juan A. Pineda | Zendy; J Santos | Zendy; Antonio Rivero | Zendy; L. Abdel-Kader | Zendy; Rosario Palacios | Zendy; Ángela Camacho | Zendy; Fernando Lozano | Zendy; Juan Macı́as | Zendy

Open Access

Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis

Author(s) -

Juan A. Pineda,

J Santos,

Antonio Rivero,

L. Abdel-Kader,

Rosario Palacios,

Ángela Camacho,

Fernando Lozano,

Juan Macı́as

Publication year - 2008

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkn045

Subject(s) - ritonavir , medicine , atazanavir , gastroenterology , cirrhosis , bilirubin , hepatitis c , hepatitis b , transaminase , viral load , immunology , human immunodeficiency virus (hiv) , antiretroviral therapy , biology , biochemistry , enzyme

To appraise the rate of grade 3-4 transaminase elevations (TEs) and grade 4 total bilirubin elevation (TBE) in patients co-infected with human immunodeficiency virus (HIV) and hepatitis C or hepatitis B virus (HCV or HBV, respectively) who receive atazanavir/ritonavir. Moreover, the relationship between these events and the degree of prior liver fibrosis was evaluated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research